AiCure

• AiCure Site Services - Reduced clinical tech burden so site personnel can increase focus on patients Transparent collaborations with industry and academia to sharpen insights into disease progression and patient behavior

OpenDBM is an open-source platform for the scientific community to access AiCure’s digital biomarker algorithms and apply them to their own data sets to measure patient behavior, encouraging research collaboration to drive innovation and improve understanding of disease symptomatology

Flexibility To Support Decentralized Trials and Traditional Site-based Trials

Data collected using AiCure’s secure, patient-facing application can support safety and efficacy endpoints and provide a comprehensive view of how therapy impacts patients AiCure supports the entire spectrum of trials, from traditional site-based trials to site-less, decentralized or virtual trials

Curious about improving medication adherence or deploying digital biomarkers? Our featured resources describe the latest innovation in these areas Learn how life science companies are transforming drug development with AiCure

Using Smartphones to Measure Symptoms of Schizophrenia Unleashing the Operational Value of Real-Time Dosing Data From Predicting Adherence to Health Outcomes – The Power of Predictive Insights Mitigating Bias in AI: Holding Innovation to a Higher Standard Good Machine Learning Practice: The First Step Toward Transparency & Trust Inspiration On-Demand: How AI is Giving Tech-Savvy Study Teams an Edge AiCure customers are dedicated to elevating clinical research We are grateful for their support and recognition

"Having worked with AiCure, they are probably the most advanced in facial recognition and mapping software and the algorithms underlying that to detect subtle clinical changes.”

Matthew Leoni, MD MBA, VP, Global Clinical Development at Cerevel Therapeutics

“The thing I’ve been focusing on is really using AiCure for, rather than a passive data collection tool, is to drive action.”

Sarah Titus, Director of Clinical Operations & Development at Sage Therapeutics

"We did see drop-out rates fall considerably and cut down by more than half. That for us is a big win."

Kyle Holen, MD, Head of Development Design Center at Abbvie

Get the latest in your inbox

Sign up today to receive updates and access to exclusive content